Healthcare Industry News: fractional flow reserve
News Release - September 21, 2010
Volcano Drives Innovation Forward With Three New U.S. Product Launches at TCT 2010SAN DIEGO, Sept. 21 -- (Healthcare Sales & Marketing Network) -- Volcano Corporation (Nasdaq:VOLC ) today announced the company's plans to launch Eagle Eye® Platinum, PrimeWire PRESTIGE™, and the s5™/s5i™ 3.2.1 Software at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting from September 21 - 25 in Washington DC. These are three significant new product innovations and updates to Volcano's unique and innovative intravascular product portfolio.
"Volcano's commitment to listening to physicians and delivering the innovative products they ask for will be evident again at this year's TCT with these three new product launches as well as our excitement about our deep pipeline of new technologies which includes Image Guided Therapy balloon and IVUS combination devices, Optical Coherence Tomography (OCT), Forward Looking IVUS, Forward Looking ICE, and Impact Microcatheters," commented Scott Huennekens, President and CEO of Volcano. "Volcano's products have now been used to help clinicians improve patient outcomes in over 1 million interventions. Our track record of innovation and physician support has elevated Volcano to U.S. market leadership in intravascular imaging. Our goal is to provide physicians with tools that will improve patient outcomes and make PCI more efficient and cost-effective. While health care cost concerns are top-of-mind, Volcano innovates in an effort to serve reduce costs and improve quality of care for patients."
"At TCT this year, Volcano is launching three major new products designed to make FFR and intravascular imaging faster and easier," said Joe Burnett, Executive Vice President of Marketing. "In an economic environment that has challenged innovation, we are pleased to be in a position where we can talk about not one, but three new products. It is this track record of innovation, and our unique, integrated system that combines both imaging and FFR, that has helped us earn the number one market share position in the U.S."
Volcano will feature three new, internally-developed products that enhance its suite of integrated cath lab systems, coronary and peripheral IVUS catheters, and physiology guide wires measuring both pressure and flow. These three products, which are all available for sale in the U.S. and Europe, include:
* Eagle Eye® Platinum is an optimization of the #1 digital IVUS catheter, designed for improved deliverability with the convenience of radiopaque markers for fast, simple length estimation;
* PrimeWire PRESTIGE™, the next generation fractional flow reserve (FFR) wire with a familiar frontline tip, better torque and more support for challenging lesions; and
* The s5™/s5i™ 3.2.1 software, which streamlines the workflow for both IVUS and FFR procedures and is compatible with more than 3,000 Volcano systems installed worldwide.
Volcano will also highlight its extensive pipeline of imaging and therapy products including the VIBE® RX Vascular Imaging Balloon Catheter (CE Mark approved), Valet™ Micro Catheter and Forward Looking Imaging (both pending US 510(k) clearance). All products will be available for demonstration at Booth #1517. Volcano's IVUS and FFR technologies will also be highlighted in other companies' booths, including those of GE Healthcare, Philips Healthcare, and Abbott Vascular.
"New imaging and FFR advances have helped remove some historic friction to using these technologies but the clinical need to look beyond the angiogram is essential," continued Burnett. "This year at TCT, there are more than 120 different presentations discussing intravascular imaging and physiology, not including structural heart presentations. The evidence for these tools is expanding, as is the conviction of many physicians that such precise tools should be used more often."
About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the potential benefits of the products and procedures described above, further development and expansion, regulatory approval, commercial release and market adoption of the company's technology, and the impact of clinical and other technical data. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission, including the current report on Form 8-K filed September 13, 2010. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.